$-0.02
(Market cap
$7 Mln
Recently Viewed
Clear AllMarket cap
$7 Mln
Revenue (TTM)
$-- Mln
P/E Ratio
--
P/B Ratio
0.3
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-- Mln
ROE
-0.1 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-0.5
Debt to Equity
0.2
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
6,346,823
CFO
$-82.64 Mln
EBITDA
$-95.29 Mln
Net Profit
$-66.73 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aptorum Group Limited Class A - ADR
| -15.4 | -25.9 | -6.7 | -6.6 | -31.3 | -48.6 | -- |
|
BSE Sensex
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Aptorum Group Limited Class A - ADR
| -62.1 | -55.5 | -63.3 | -39.3 | -84.4 | 4.4 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aptorum Group Limited Class A - ADR
|
0.9 | 7.3 | 0.0 | -1.4 | -- | -6.2 | -- | 0.3 |
| 1.3 | 10.3 | 18.7 | -2.0 | 25.4 | -3.9 | -- | 0.2 | |
| 16.5 | 847.6 | 107.5 | 105.9 | -1.8 | 44.8 | 8 | 2.8 | |
| 3.3 | 1.9 | 17.9 | -3.7 | -- | -7.2 | -- | 0.0 |
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include... SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. In addition, it is developing NLS-1, which is in preclinical trial for the treatment of endometriosis; DLS-1+2, which is in preclinical trial to treat NSCLC with mutation; DLS-3, which is in preclinical trial to treat autoimmune disease; CLS-1, a macromolecule, which is in preclinical trial to treat obesity; and CLS-1 and CLS-3. Further, the company offers NativusWell DOI (NLS-2), a dietary supplement for women undergoing menopause; and provides management services. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Read more
Founder, CEO & Non-Executive Director
Mr. Chung Yuen Huen
Founder, CEO & Non-Executive Director
Mr. Chung Yuen Huen
Headquarters
London
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Aptorum Group Limited Class A - ADR is $0.90 (NASDAQ) as of 24-Apr-2026 16:00 EDT. Aptorum Group Limited Class A - ADR has given a return of -31.33% in the last 3 years.
Since, TTM earnings of Aptorum Group Limited Class A - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
-2.13
|
2.26
|
The 52-week high and low of Aptorum Group Limited Class A - ADR are Rs 4.47 and Rs 0.65 as of 26-Apr-2026.
Aptorum Group Limited Class A - ADR has a market capitalisation of $ 7 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Aptorum Group Limited Class A - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.